Radioimmunotherapy (RIT)
Radio immunotherapy (RIT) is a combination of radiation therapy and immunotherapy used to treat non-Hodgkin B-cell lymphoma and other types of cancer. RIT uses engineered monoclonal antibodies paired with radioactive materials called radiotracers. When injected into the patient’s bloodstream, they bind to cancer cells and deliver a high dose of radiation directly to the tumor. In RIT, a monoclonal antibody is paired with a radioactive material, or radiotracer. When injected into the patient’s bloodstream, the radiation-linked monoclonal antibody, or agent, travels to and binds to cancer cells, allowing a high dose of radiation to be delivered directly to the tumor.
Related Conference of Radioimmunotherapy (RIT)
Radioimmunotherapy (RIT) Conference Speakers
Recommended Sessions
- Advances in Medical Imaging and Diagnosis
- Adaptive radiotherapy
- Angiogenesis Inhibitors
- Biomarkers
- Cancer Biopsy
- Cancer Drug Resistance & Cancer Vaccine
- Cancer Genomics
- Cancer Screening, Diagnosis & Prevention
- Chemotherapy
- Hormone Therapy
- Image guided radiotherapy
- Immunotherapy
- Medical Imaging
- Neuro interventional radiology
- Nuclear Medicine
- Positron Emission Tomography and Computed Tomography (PET-CT) Scans
- Precision Medicine
- Proton Therapy
- Radiation Therapy
- Radioimmunotherapy (RIT)
- Radiopharmaceutical Chemistry
- Stem Cell Transplant
- Targeted cancer therapies
- Tumor Microenvironment